<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The outcome for patients presenting with <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (BLARF) without dialysis is poor </plain></SENT>
<SENT sid="1" pm="."><plain>This was a retrospective non-randomized comparative study designed to determine the outcome of two different treatment protocols </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: One group of patients (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) received oral <z:chebi fb="0" ids="40279">allopurinol</z:chebi>, intravenous (IV) <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="47426">furosemide</z:chebi>, 8.4% <z:chebi fb="17" ids="32139">sodium bicarbonate</z:chebi>, and intrathecal (IT) <z:chebi fb="0" ids="44185">methotrexate</z:chebi>; the other (TPB) alternate day IV infusion of low dose cyclosphosphamide (125 mg/m(2) x 4 doses), IT <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (Days 1 and 5) and aggressive pre-emptive anti-<z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> therapy including oral <z:chebi fb="0" ids="40279">allopurinol</z:chebi> and calcium <z:chebi fb="4" ids="24996">lactate</z:chebi>, IV calcium <z:chebi fb="1" ids="24265">gluconate</z:chebi>, <z:chebi fb="1" ids="2549">salbutamol</z:chebi>, insulin and infusions of <z:chebi fb="0" ids="47426">furosemide</z:chebi>, <z:chebi fb="17" ids="32139">sodium bicarbonate</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Nine of 16 received <z:chebi fb="6" ids="15702,53394">TPA</z:chebi>, 7 received TPB </plain></SENT>
<SENT sid="4" pm="."><plain>Post chemotherapy <z:hpo ids='HP_0001903'>anemia</z:hpo> was more severe with <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>TPB patients received significantly more chemotherapy than those in <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> (P = 0.04) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 16 had <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> (TLS) </plain></SENT>
<SENT sid="7" pm="."><plain>Six of nine patients with <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> died from this (three from other causes), two <z:hpo ids='HP_0011420'>deaths</z:hpo> in TPB were due to causes other than <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lysis </plain></SENT>
<SENT sid="8" pm="."><plain>Other evaluated outcome indices were similar in both groups </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Slow IV infusion of low dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> given on alternate days in addition to pre-emptive anti-TLS measures (TPB) were associated with better outcome in BLARF patients compared to a high dose multiple chemotherapy regimen (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) </plain></SENT>
</text></document>